- Coeptis Therapeutics, Inc. (NASDAQ:COEP) has a Return on Invested Capital (ROIC) of -145.07%, indicating it is not generating sufficient returns to cover its cost of capital.
- Cardio Diagnostics Holdings, Inc. (CDIO) shows the least negative ROIC to WACC ratio among its peers, suggesting better capital efficiency.
- All companies in the biotechnology sector, including Coeptis, are struggling to achieve positive returns relative to their cost of capital, highlighting the sector’s high-risk nature.
Coeptis Therapeutics, Inc. (NASDAQ:COEP) is a company focused on developing innovative therapies for patients with unmet medical needs. The company operates in the biotechnology sector, which is known for its high-risk, high-reward nature. Coeptis competes with other biotech firms like Cardio Diagnostics Holdings, Inc. (CDIO), ZyVersa Therapeutics, Inc. (ZVSA), SeaStar Medical Holding Corporation (ICU), and Dermata Therapeutics, Inc. (DRMA).
In evaluating Coeptis’s financial performance, the Return on Invested Capital (ROIC) is a critical metric. Coeptis has a ROIC of -145.07%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 5.86%. This results in a ROIC to WACC ratio of -24.77, indicating that Coeptis is not generating sufficient returns to cover its cost of capital.
Comparatively, Cardio Diagnostics Holdings, Inc. (CDIO) has a ROIC of -60.70% and a WACC of 17.37%, leading to a ROIC to WACC ratio of -3.50. Despite being negative, CDIO’s ratio is the least negative among its peers, suggesting it is relatively more efficient in capital utilization. This positions CDIO as a more attractive option for investors seeking better capital efficiency.
ZyVersa Therapeutics, Inc. (ZVSA) and SeaStar Medical Holding Corporation (ICU) also show negative ROIC to WACC ratios of -8.29 and -42.65, respectively. These figures highlight the challenges these companies face in generating returns above their cost of capital. Dermata Therapeutics, Inc. (DRMA) has a ROIC to WACC ratio of -27.17, which is slightly worse than Coeptis, further emphasizing the difficulties in this sector.
Overall, the analysis reveals that all companies, including Coeptis, are struggling to achieve positive returns relative to their cost of capital. However, Cardio Diagnostics Holdings, Inc. (CDIO) emerges as the least negative, indicating a relatively better position in terms of capital efficiency among its peers.
